Morgan Stanley Maintains Equal-Weight on GRAIL, Raises Price Target to $120

10/13/2026
Impact: 50
Healthcare

Morgan Stanley analyst Tejas Savant has maintained an Equal-Weight rating on GRAIL (NASDAQ: GRAL) and raised the price target from $60 to $120. This adjustment reflects a positive outlook on the company's performance.

AI summary, not financial advice

Share: